Get the Stockscreener App
1.4051
6.02%
0.0751
Prokidney Corp stock is traded at $1.4051, with a volume of 595.38K.
It is up +6.02% in the last 24 hours and down -12.96% over the past month.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
See More
Previous Close:
$1.33
Open:
$1.32
24h Volume:
595.38K
Relative Volume:
0.50
Market Cap:
$293.54M
Revenue:
$889.00K
Net Income/Loss:
$-156.28M
P/E Ratio:
-2.6677
EPS:
-0.5267
Net Cash Flow:
$-150.06M
1W Performance:
-16.57%
1M Performance:
-12.96%
6M Performance:
-30.20%
1Y Performance:
-40.25%
1-Day Range:
$1.31
$1.41
1-Week Range:
$1.30
$1.68
52-Week Range:
$1.30
$3.4799
Prokidney Corp Stock (PROK) Company Profile
Name
Prokidney Corp
Sector
Industry
Phone
336-999-7028
Address
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.405 | 277.87M | 889.00K | -156.28M | -150.06M | -0.5267 |
VRTX
Vertex Pharmaceuticals Inc
|
515.63 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.26 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
991.71 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.75 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.20 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | H.C. Wainwright | Buy |
| Jun-30-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-30-24 | Initiated | JP Morgan | Neutral |
| Sep-10-24 | Initiated | Guggenheim | Buy |
| Mar-07-24 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-23 | Initiated | BTIG Research | Buy |
| Dec-21-22 | Initiated | Jefferies | Buy |
| Nov-10-22 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-18-22 | Initiated | UBS | Buy |
| Oct-14-22 | Initiated | Citigroup | Buy |
| Sep-23-22 | Initiated | BofA Securities | Buy |
| Sep-02-22 | Initiated | Evercore ISI | Outperform |
View All
Prokidney Corp Stock (PROK) Latest News
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) (PROK) - Seeking Alpha
What is HC Wainwright's Estimate for ProKidney Q3 Earnings? - MarketBeat
ProKidney Corp. (PROK) Slides 9.3% to $1.46 as Key Support Level Comes into FocusVolume Breakout Ideas - dars.gov.et
Morgan Stanley (PROK) filings show ProKidney stake at 4.7% and below 5% level - Stock Titan
ProKidney FY2030 EPS Estimate Decreased by HC Wainwright - MarketBeat
ProKidney reports larger second-quarter loss as key clinical trial expenses mount - Winston-Salem Journal
ProKidney earnings missed, revenue topped estimates By Investing.com - Investing.com Nigeria
ProKidney Corp (PROK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProKidney earnings missed, revenue topped estimates - Investing.com
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
ProKidney completes Phase 3 PROACT 1 accelerated approval enrollment - scanx.trade
ProKidney (NASDAQ:PROK) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
ProKidney reports Q2 revenue of $150,000 as PROACT 1 advances - Quiver Quantitative
Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise - TradingView
PROK: Completed key Phase 3 trial enrollment; cash supports operations into mid-2027 - TradingView
ProKidney Corp. (NASDAQ: PROK) warns on cash runway after $89M H1 loss - Stock Titan
ProKidney Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights - GlobeNewswire
ProKidney Corp (PROK) Stock News Today - TradingKey
ProKidney Corp. (PROK) director converts paired units into Class A stock - Stock Titan
3 Promising Penny Stocks With Market Caps Under $500M - simplywall.st
PROK Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
ProKidney (PROK) to Release Quarterly Earnings on Tuesday - marketbeat.com
ProKidney Corp. Revenue Breakdown – NASDAQ:PROK - TradingView
PROK Q2'26 Earnings: revenue estimate is 186.25K USD - TradingView
ProKidney Corp (PROK) Income Statement - TradingKey
PROK|ProKidney Corp|Price:1.565|Chg%:+0.025 - TradingKey
ProKidney Corp (PROK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProKidney Corp (PROK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ProKidney Corp (PROK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProKidney Corp (PROK) Balance Sheet - TradingKey
ProKidney Corp (PROK) Cash Flow - TradingKey
PROK|ProKidney Corp|Price:1.504|Chg%:+0.004 - TradingKey
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrower Loss as Clinical Pipeline AdvancesFiscal Year Earnings - dars.gov.et
ProKidney Corp (PROK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProKidney (NASDAQ:PROK) Trading Down 0.7%Time to Sell? - MarketBeat
ProKidney Corp. (PROK) Q1 2026 Earnings: In-Line EPS, Pre-Revenue Progress Drives Modest Stock GainROA Comparison - dars.gov.et
Meet the Biotech Stock That Rocketed 775% Higher - MSN
ProKidney Corp (PROK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProKidney Corp. Q1 2026 Earnings: Clinical-Stage Biotech Posts Narrower-Than-Expected Loss, Shares RallyEPS Revision Trend - dars.gov.et
ProKidney Corp. (PROK) Declines Sharply: Key Support Level Under ScrutinyMFI Overbought - dars.gov.et
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrowed Loss Slightly Beats Estimates Amid Pipeline Focus - dars.gov.et
ProKidney (NASDAQ:PROK): Can This Penny Stock Rebound? - Kalkine Media
What Makes ProKidney Corp (NASDAQ:PROK) Stand Out on Nasdaq Composite? - Kalkine Media
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEstimate Uncertainty - dars.gov.et
ProKidney (PROK) 43rd Annual J.P. Morgan Healthcare Conference 2025 Summary - Quartr
ProKidney (NASDAQ: PROK) CTO awarded 750,000 stock options at $1.89 strike - Stock Titan
July 2026 Penny Stocks With Promising Potential - simplywall.st
PROK Q1 2026 Earnings: EPS Slightly Exceeds Estimates as Clinical Progress ContinuesRevenue Guidance Range - dars.gov.et
PROKProKidney Corp Short Interest - Finviz
Is ProKidney (NASDAQ:PROK) In A Good Position To Invest In Growth? - 富途牛牛
Prokidney Corp Stock (PROK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Prokidney Corp Stock (PROK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pereira Brian JG | Director |
Nov 12 '25 |
Sale |
2.72 |
255,026 |
694,515 |
54,333 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):